INTRODUCTION

Within a few weeks of the first report of coronavirus disease 2019 (COVID-19) in Wuhan, China, the first case of COVID-19 was confirmed in South Korea [1]. Subsequently, there was an exponential increase in the number of COVID-19 cases in South Korea during February and March 2020 [2]. In May 2020, of the 11,344 virus-positive patients in the whole of Korea, 65% (6,880 patients) were in the fourth-largest city, Daegu, because of a large outbreak that was attributed to a religious assembly. Among the patients, those whose symptoms were mild were primarily cared for at “therapeutic living centers,” whereas acutely and severely ill patients were admitted to five university hospitals in Daegu [3]. These hospitals had readily available high-flow nasal cannulae, mechanical ventilation, continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), and intensive care units (ICUs), the provision of which was managed by mutual cooperation among the staff of the hospitals. Therefore, patients with COVID-19 in the Daegu region who were admitted to these hospitals were moderately-to-severely ill, but were cared for appropriately and in a timely fashion.

Patients with diabetes mellitus (DM) or hyperglycemia are susceptible to infection because of defects in their innate immunity that result in defective phagocytosis and neutrophil chemotaxis [45]. Moreover, among several risk factors, DM per se is considered to be a major contributor to the severity and mortality rate associated with previously identified respiratory viral infections, including Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus 2 [67]. Therefore, DM is considered to be an important risk factor for the severity of and mortality associated with COVID-19. Furthermore, some previous studies have shown that DM increases the mortality rate of patients with COVID-19 [89], although others did not show a difference in mortality between COVID-19 patients with or without DM [1011]. Because individuals with DM tend to be older and have more co-morbidities than those without DM, the assessment of DM as an independent risk factor for COVID-19 outcomes is challenging. In addition, because COVID-19 infection, as its nomenclature suggests, is a novel viral disease, the impact of DM on the outcome of resulting disease has yet to be fully and appropriately assessed.

Therefore, in the present study, we determined whether the presence of DM affected the severity or mortality of COVID-19 by comparing patients with or without DM, and patients who were matched 1:1 using propensity score (PS)-matching.

METHODS

Study design and participants

We conducted a multi-center, retrospective, observational study. The study protocol was approved by the Institutional Review Board of Keimyung University Dongsan Hospital (2020-04-111) and individually by the Institutional Review Boards of each collaborating hospital. The necessity for informed consent was waived by the ethics boards of the hospitals because of the retrospective study design.

The study participants comprised adult patients (age >18 years) with COVID-19 that was laboratory-confirmed between 18 February 2020 and 31 March 2020. They were recruited from university hospitals (Daegu Catholic University Hospital, Keimyung University Dongsan Medical Center [Dongsan Hospital and Daegu Dongsan Hospital], Kyungpook National University Hospital, Kyungpook National University Chilgok Hospital, and Yeungnam University Hospital) in Daegu.

COVID-19 was diagnosed using a reverse transcription-polymerase chain reaction (RT-PCR) assay of nasal or pharyngeal swab specimens, and a confirmed case of COVID-19 was defined using a positive result on RT-PCR, irrespective of the clinical signs and symptoms present. A total of 1,100 patients were included in the study. Patients who were diagnosed with re-positive COVID-19 were excluded from the study. Patients who were admitted to more than two hospitals because of referral within the cohort were counted as a single case. After the exclusion of 18 patients, 1,082 were enrolled and allocated to a DM (n=235) or a non-DM (n=847) group. After PS-matching, 235 DM patients and 235 non-DM patients who had been matched for age, sex, and the presence of underlying disease (hypertension, cerebrovascular disease, cardiovascular disease, chronic kidney disease, chronic pulmonary disease, and cancer) were also compared (Fig. 1).

Data collection and definitions

We collected data from electronic medical records regarding the age, sex, vital signs, co-morbidities (hypertension, cerebrovascular disease, cardiovascular disease, chronic kidney disease, chronic pulmonary disease, and cancer), medication, laboratory findings, presence of pneumonia on chest radiographs or computed tomography (CT), treatment modality, and outcomes during hospitalization for all the participants. The major symptoms present (fever, cough, sputum, rhinorrhea, sore throat, myalgia, diarrhea, and shortness of breath) were also recorded. The laboratory findings included routine blood tests, glycosylated hemoglobin (HbA1c), C-reactive protein (CRP), procalcitonin, and serum indicators of liver or kidney injury. The presence of DM was defined on the basis of the participants' medical history and the diagnostic criteria for DM of the Korean Diabetes Association [12]. Release from quarantine was defined using the instructions from the Korean Central Disease Control Headquarters: (1) clinically, the absence of a fever, without the necessity for an anti-pyretic agent, and an improvement in symptoms; (2) negative results of PCR tests performed twice at a 24-hour interval [13]; (3) severe disease defined as the necessity for the use of a high-flow nasal cannula, mechanical ventilation, CRRT, or ECMO, or admission to an ICU.

Quantification and statistical analysis

Statistical analyses were performed using SPSS Statistics version 18.0 (SPSS Inc., Chicago, IL, USA). Continuous data are presented as means and standard deviations, and categorical data as frequency rates and percentages. Comparisons between two groups were made using Student's t-tests for continuous data and chi-square tests for categorical data. The risk of death and the corresponding hazard ratio (HR) were analyzed using the Kaplan-Meier method and a Cox proportional hazard model. Multivariate logistic analysis of the initial laboratory findings was performed to identify prognostic factors for severe disease and death from COVID-19. The relationships of severe disease and death with the current medication of patients with DM were also evaluated using multivariate logistic analysis. Differences with a two-sided α<0.05 were considered to be statistically significant.

RESULTS

Baseline characteristics of patients with COVID-19 on admission

The baseline characteristics of unmatched and PS-matched patients are shown in Table 1. A total of 1,082 patients with confirmed COVID-19 were enrolled, and 235 (21.81%) of these had DM (Table 1, Fig. 1). The mean ages of the participants were 56.5±18.0 and 68.3±11.9 years in the non-DM and DM group, respectively. Patients in their 50s were most common in the non-DM group, whereas in the DM group, patients in their 60s were most common, followed by those in their 70s (Supplementary Fig. 1). Five hundred and sixty-nine participants (67.2%) in the non-DM group and 129 (54.9%) in the DM group were women (P<0.01) (Table 1). After PS-matching, the percentages of women were 59.6% and 54.9%, respectively (P>0.05). As expected, patients with DM (73.7%) had more co-morbidities than those without DM (37.8%) (Table 1). After PS-matching, however, the prevalences of co-morbidities, such as hypertension, cerebrovascular accident, heart disease, chronic kidney disease, and cancer, did not differ between the two groups (Table 1). Among the participants with DM, 8.1% were using insulin. Metformin was the most commonly used oral antidiabetic drug (48.1%), followed by a dipeptidyl peptidase-4 (DPP-4) inhibitor (36.2%). With regard to antihypertensive drugs, renin-angiotensin system (RAS) inhibitors were the most commonly prescribed type of drug in the DM group, whereas calcium channel blockers were the most commonly prescribed type of drug in the non-DM group (Table 1).

Approximately 16% of the participants did not present with any symptoms. Cough, sputum, rhinorrhea, sore throat, myalgia, headache, and diarrhea, which are indicative of upper respiratory tract infection or viral infection, were more prevalent in the non-DM group of the unmatched cohort (Table 1). By contrast, dyspnea and radiographically diagnosed pneumonia were significantly more prevalent in the DM group (Table 1). Although PS-matching abrogated the differences in the prevalence of the majority of the symptoms listed above, rhinorrhea remained more common in the non-DM group (Table 1). Two-thirds of the participants were diagnosed as having pneumonia by radiologic examination following their admission. Pneumonia was more prevalent on X-ray or chest CT in the DM group than in the non-DM group, although this difference was not significant in the PS-matched cohort (P=0.08). Analysis of the laboratory findings on admission showed higher HbA1c, serum glucose concentration, white blood cell (WBC) count, serum CRP, lactate dehydrogenase (LDH) activity, blood urea nitrogen, and creatinine; and lower lymphocyte count and serum albumin in participants with DM in the unmatched cohort. Furthermore, even after PS-matching, there were significantly higher serum glucose, HbA1c, LDH, and neutrophil count; and significantly lower lymphocyte count and serum albumin concentration. However, the serum CRP and creatinine concentrations were not significantly different (Table 1).

In-hospital management and outcomes

The number of deaths in the entire cohort was 85 (mortality rate, 7.85%) (Table 2). During hospitalization, 152 participants (14.04%) had severe disease, which was defined as a reliance on one or more of ICU care, high-flow O₂ nasal cannulae, mechanical ventilation, CRRT, or ECMO (Table 2). In the PS-matched cohort, more of the participants with DM developed severe disease than those without DM (Table 2). The prevalence of quarantine release was also significantly lower in the DM group (Table 2). In addition, in the unmatched cohort, the period of time between COVID-19 confirmation and quarantine release, and the duration of stay in hospital, were significantly longer in participants with DM than in those without DM (Table 2). However, after PS-matching, these differences were not statistically significant (Table 2).

The mortality rate was significantly higher in the DM group than in the non-DM group (18.7% vs. 7.7%) (Table 2). Not only in the entire cohort (Fig. 2A), but also in PS-matched participants, the DM group exhibited higher mortality than the non-DM group, as illustrated by the cumulative death rate (HR, 2.40; 95% confidence interval [CI], 1.38 to 4.15) (Fig. 2B).

We also stratified the PS-matched cohort according to their age and sex. Subgroup analysis showed that DM significantly increased the risk of mortality in participants aged ≥70 years (HR, 3.29; 95% CI, 1.72 to 6.32) (Fig. 3B), whereas DM did not increase this risk in participants aged <70 years (HR, 1.06; 95% CI, 0.36 to 3.32) (Fig. 3A). DM was associated with higher mortality, irrespective of sex (Fig. 3C and D).

Identification of the baseline laboratory parameters that influence the severity of COVID-19-related disease and death

Multivariate logistic analysis showed that high baseline WBC count, high hemoglobin concentration, low platelet count, low albumin concentration, and high aspartate aminotransferase (AST) activity were associated with a higher risk of death in participants with DM (Table 3). Low platelet count, high AST activity, low alanine aminotransaminase (ALT) activity, and high LDH activity were associated with severe disease (Table 3). Among participants with DM, the baseline random serum glucose and CRP concentrations were not associated with severe disease or death (Table 3). However, among non-DM participants, high CRP concentration, low albumin concentration, high AST activity, and low ALT activity were predictors of severe disease. Of these, only high AST activity was also a predictor of death (Table 3).

Analysis of the relationships between the use of particular medications and in-hospital mortality

Angiotensin-converting enzyme 2 (ACE2) inhibitor and DPP-4 inhibitor use appear to affect the pathogenesis of coronaviruses [1415]. Therefore, we next investigated whether the prior use of such medications affected the prognosis or mortality rate of participants with COVID-19, after adjustment for age, sex, and the presence of underlying diseases. As shown in Supplementary Table 1, the use of neither a RAS inhibitor nor a DPP-4 inhibitor was associated with higher prevalence of severe disease or death. Instead, the use of metformin or insulin tended to be associated with less severe disease and lower mortality, although these findings did not achieve statistical significance (Supplementary Table 1).

DISCUSSION

In the present study, we showed that patients with DM are at higher risk of severe COVID-19-related disease and mortality. Given the importance of the relationship between COVID-19 and DM, an international panel of experts has recently made practical recommendations for the management of DM in patients with COVID-19 [16]. Our findings underscore the importance of taking extra care of patients with DM who contract COVID-19.

In the present study, 21.8% of patients with COVID-19 had DM. A previous meta-analysis showed a mean prevalence of DM of 11% among patients with COVID-19 [9]. Because of the exponential increase in COVID-19 infections, doctors from the Daegu Medical Associations performed telephone consultations to check the status of patients who were confined at home and classified them on the basis of their disease severity. They were hospitalized if they exceeded a threshold score on a scoring system that consisted of the severity of disease, age, the presence of underlying disease, and social factors. Asymptomatic or mild cases were admitted to a “therapeutic living center” and closely monitored, whereas those with moderate-to-severe disease were admitted to university hospitals [3]. On the basis of the scoring system, most of the participants in the present study were classified as having moderate-to-severe disease.

The prevalence of DM in the present study cohort was almost twice that of the general population, presumably because individuals with severe disease who were at high risk of severe disease or death were preferentially admitted to the university hospitals. Notably, unlike in other recently published studies [1718], female patients made up the larger proportions of both the non-DM and DM groups in the present study. This is in contrast to the Chinese data [18] and data from another region of Korea [19]. This difference might be attributable to a specific demographic characteristic: the exponential spread of the virus in Daegu was initiated in a female-dominated religious group.

DM is an independent risk factor for the severity of and mortality associated with COVID-19 [920]. A previous large cohort study (a cohort of 7,336 COVID-19 patients with or without DM) showed that DM increases the mortality of patients and that strict glucose control improves the outcomes of COVID-19 [17]. An analysis of 1,950 COVID-19 patients also revealed that DM is a risk factor (HR, 1.59; 95% CI, 1.03 to 2.45) [8]. In addition, a meta-analysis showed that DM in patients with COVID-19 is associated with two-fold higher mortality compared with patients without DM [9]. These findings are highly suggestive that DM is an important factor in the prognosis of COVID-19. Nevertheless, several COVID-19 studies have not shown significant differences in disease severity or mortality in patients with or without DM, presumably because of the small numbers of participants [1021]. In addition, a recent observational study showed that DM is not an independent risk factor for COVID-19-related mortality [11].

The findings of the present study also show that DM is associated with a higher risk of severe disease and mortality, regardless of sex. Furthermore, we identified a relationship between the presence of DM and higher mortality due to COVID-19 in older patients, but this relationship was not present in younger patients. A series of recent studies suggest that old age is a risk factor for mortality in patients with DM [1122], but this evidence is insufficient to conclude that DM is not a risk factor for COVID-19-related mortality in young patients. However, on the basis of the results of the present study, it is possible to surmise that DM is more likely to be a risk factor in older patients than in younger patients.

In the present study, we did not identify any relationships between the use of specific medications and the outcomes associated with COVID-19 in DM patients. DPP-4 is a receptor for the human coronavirus-Erasmus Medical Center (hCoV-EMC) [15]. Although it is not clear whether this is also the case for COVID-19, and early studies have failed to identify relationships between the exposure to DPP-4 inhibitors and the outcomes of COVID-19 [23], an upregulation of DPP-4 in patients with type 2 DM remains a plausible explanation for the greater severity of COVID-19 in patients with DM [24]. Furthermore, it has been suggested that the ACE2 receptor is the primary receptor for coronavirus spike protein [1625]. Greater glycosylation of both the spike protein and the ACE2 receptor, secondary to hyperglycemia, may modulate the binding of the virus and therefore might account for the greater severity of COVID-19 in hyperglycemic patients. In the present study, the disease was slightly less severe in patients who were administering metformin or insulin, but this trend did not achieve statistical significance. Furthermore, the use of RAS inhibitors did not affect mortality. The effect of medication on the mortality associated with COVID-19 remains controversial [23262728]. Therefore, our findings are in line with recent recommendations that unless contraindicated, the continuation of current medication is strongly recommended [1729].

The present study had some limitations. First, after the diagnosis of the 31st case of COVID-19 in South Korea, there was an exponential increase in the number of COVID-19 diagnoses in Daegu. Because of a shortage of infrastructure and training of medical staff, there was incomplete documentation regarding exposure history and laboratory testing conducted in the patients. In particular, and as previously documented [22], HbA1c values for a considerable proportion of the participants were missing; therefore, our analysis of the impact of the degree of baseline glycemic control (i.e., HbA1c on admission) on the severity and mortality associated with COVID-19 was limited. Second, of the confirmed cases of COVID-19 in Daegu, 65.6% were associated with a single religious group, so it is unlikely that the data collected are representative of the general population. Furthermore, these patients were admitted to university hospitals because of their moderate-to-severe disease, and therefore the data are not representative of COVID-19 patients with mild disease. However, in spite of these limitations, the present study has a substantial strength: it is the first multi-center study to investigate the association between COVID-19 and DM in Daegu, Korea, the site of the first outbreak of COVID-19 outside Wuhan, China.

Our findings regarding severe COVID-19 patients corroborate a series of recent observations that DM is a risk factor for severe COVID-19-related disease, as well as mortality. Accumulating evidence and our own data both also suggest that old age is an independent risk factor for COVID-19 infection and the severity of the disease. The present findings strongly suggest that DM contributes to higher COVID-19-related mortality, especially in the elderly. Therefore, special attention should be paid to older patients with DM during the treatment of COVID-19.

Acknowledgements

ACKNOWLEDGMENTS

This study was supported by a research grant from the Daegu Medical Association COVID-19 Scientific Committee. We also would like to express sincere gratitude to all the members of the Daegu-Gyeongbuk Diabetes and Endocrinology Society who actively participated in the study.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTIONS:

• Conception or design: J.S.M.

• Acquisition, analysis, or interpretation of data: M.K.K., J.H.J., S.W.K., J.S.M., N.H.C., E.H., J.H.Y., J.Y.L., M.H., J.S.P., Y.S.K., Y.K.C., K.T.K., S.Y.L., E.J.J., J.W.K., H.L.H., H.H.K., C.Y.J., Y.Y.L., E.H., S.M.C., J.H., J.H.A., N.K, S.W.K., H.H.C., Y.H.L., J.L., K.G.P., H.A.K., J.H.L.

• Drafting the work or revising: M.K.K., J.H.J.

• Final approval of the manuscript: M.K.K., J.H.J., S.W.K., J.S.M.

SUPPLEMENTARY MATERIALS

REFERENCES

• 1. COVID-19 National Emergency Response Center. Epidemiology and Case Management Team. Korea Centers for Disease Control and Prevention. Coronavirus disease-19: summary of 2,370 contact investigations of the first 30 cases in the Republic of Korea. Osong Public Health Res Perspect 2020;11:81-84. ArticlePubMedPMCPDF
• 2. COVID-19 National Emergency Response Center. Epidemiology and Case Management Team. Korea Centers for Disease Control and Prevention. Coronavirus disease-19: the first 7,755 cases in the Republic of Korea. Osong Public Health Res Perspect 2020;11:85-90. ArticlePubMedPMCPDF
• 3. Kim SW, Lee KS, Kim K, Lee JJ, Kim JY. Daegu Medical Association. A brief telephone severity scoring system and therapeutic living centers solved acute hospital-bed shortage during the COVID-19 outbreak in Daegu, Korea. J Korean Med Sci 2020;35:e152. ArticlePubMedPMCPDF
• 4. Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci 2016;351:201-211. ArticlePubMed
• 5. Turina M, Fry DE, Polk HC Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med 2005;33:1624-1633. ArticlePubMed
• 6. Cristelo C, Azevedo C, Marques JM, Nunes R, Sarmento B. SARS-CoV-2 and diabetes: new challenges for the disease. Diabetes Res Clin Pract 2020;164:108228. ArticlePubMedPMC
• 7. Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East respiratory syndrome. Lancet 2020;395:1063-1077. ArticlePubMedPMC
• 8. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX. China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547. ArticlePubMedPMC
• 9. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, Khare S, Srivastava A. Is diabetes mellitus associated with mortality and severity of COVID-19?: a meta-analysis. Diabetes Metab Syndr 2020;14:535-545. ArticlePubMedPMC
• 10. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020 3 31 [Epub].
• 11. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG. ISARIC4C investigators. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985. ArticlePubMedPMC
• 12. Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, Park SO, Hur KY, Chon S, Moon MK, Kim NH, Kim SY, Rhee SY, Lee KW, Kim JH, Rhee EJ, Chun S, Yu SH, Kim DJ, Kwon HS, Park KS. Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J 2019;43:398-406. ArticlePubMedPMCPDF
• 13. Ministry of Health and Welfare. Central Disaster Management Headquarters cited 2020 Jul 8. Available from: http://ncov.mohw.go.kr.
• 14. Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell 2020;78:779-784. ArticlePubMedPMC
• 15. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495:251-254. ArticlePubMedPMCPDF
• 16. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RI, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Vidal J, Geloneze B, Chan JC, Ji L, Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8:546-550. ArticlePubMedPMC
• 17. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-1720. ArticlePubMed
• 18. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen MM, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang C, Zhang Z, Lu Z, Wang J, Lu H, Xia X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y, Huang X, Guo J, Zhang BH, Li H. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;31:1068-1077. ArticlePubMedPMC
• 19. Korean Society of Infectious Diseases. Korean Society of Pediatric Infectious Diseases. Korean Society of Epidemiology. Korean Society for Antimicrobial Therapy. Korean Society for Healthcare-associated Infection Control and Prevention. Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci 2020;35:e112. ArticlePubMedPMCPDF
• 20. Katulanda P, Dissanayake HA, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Yogendranathan N, Gamage KKK, de Silva NL, Sumanatilleke M, Somasundaram NP, Matthews DR. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia 2020;63:1440-1452. ArticlePubMedPMCPDF
• 21. Chung SM, Lee YY, Ha E, Yoon JS, Won KC, Lee HW, Hur J, Hong KS, Jang JG, Jin HJ, Choi EY, Shin KC, Chung JH, Lee KH, Ahn JH, Moon JS. The risk of diabetes on clinical outcomes in patients with coronavirus disease 2019: a retrospective cohort study. Diabetes Metab J 2020;44:405-413. ArticlePubMedPMCPDF
• 22. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, Amadou C, Arnault G, Baudoux F, Bauduceau B, Borot S, Bourgeon-Ghittori M, Bourron O, Boutoille D, Cazenave-Roblot F, Chaumeil C, Cosson E, Coudol S, Darmon P, Disse E, Ducet-Boiffard A, Gaborit B, Joubert M, Kerlan V, Laviolle B, Marchand L, Meyer L, Potier L, Prevost G, Riveline JP, Robert R, Saulnier PJ, Sultan A, Thebaut JF, Thivolet C, Tramunt B, Vatier C, Roussel R, Gautier JF, Gourdy P. CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500-1515. ArticlePubMedPMCPDF
• 23. Fadini GP, Morieri ML, Longato E, Bonora BM, Pinelli S, Selmin E, Voltan G, Falaguasta D, Tresso S, Costantini G, Sparacino G, Di Camillo B, Tramontan L, Cattelan AM, Vianello A, Fioretto P, Vettor R, Avogaro A. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study. Diabetes Obes Metab 2020 5 28 [Epub].
• 24. Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and comorbidities: a role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes 2020;12:649-658. PubMed
• 25. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol 2020;92:770-775. ArticlePubMedPMCPDF
• 26. Ursini F, Ciaffi J, Landini MP, Meliconi R. COVID-19 and diabetes: is metformin a friend or foe? Diabetes Res Clin Pract 2020;164:108167. ArticlePubMedPMC
• 27. Luo P, Qiu L, Liu Y, Liu XL, Zheng JL, Xue HY, Liu WH, Liu D, Li J. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg 2020;103:69-72. ArticlePubMedPMC
• 28. Chatterjee S. SGLT-2 inhibitors for COVID-19: a miracle waiting to happen or just another beat around the bush? Prim Care Diabetes 2020 5 28 [Epub].Article
• 29. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract 2020;163:108146. ArticlePubMedPMC

Fig. 1

Flow chart of the study. COVID-19, coronavirus disease 2019; KNUH, Kyungpook National University Hospital; DSMC, Dongsan Medical Center; KNUCH, Kyungpook National University Chilgok Hospital; DCMC, Daegu Catholic Medical Center; PCR, polymerase chain reaction; DM, diabetes mellitus; PS, propensity score.

Fig. 2

Mortality due to coronavirus disease 2019 in all patients (A) and propensity score-matched patients (B). The data were analyzed using the Kaplan-Meier method, and hazard ratios were calculated using a Cox proportional hazards model. Data are expressed as hazard ratio (HR) (95% confidence intervals [CI]). DM, diabetes mellitus

Fig. 3

Mortality of coronavirus disease 2019 patients in subgroups defined according to age and sex. Patients aged <70 years (A) and >70 years (B); and male (C) and female (D) patients. Data were analyzed using a Cox proportional hazards model. Data are expressed as hazard ratio (HR) (95% confidence intervals [CI]). The model was adjusted for age, sex, and the presence of underlying diseases.

Table 1

Baseline characteristics of the full group of participants and of propensity score-matched patients with coronavirus disease 2019

Characteristic	Unmatched patients			1:1 PS-matched patients
	Non-DM (n=847)	DM (n=235)	P value	Non-DM (n=235)	DM (n=235)	P value
Age, yr	56.5±18.0	68.3±11.9	<0.01	69.7±12.4	68.3±11.9	0.21
Male sex	278 (32.8)	106 (45.1)	<0.01	95 (40.4)	106 (45.1)	0.31
BMI, kg/m2	23.5±3.6	24.2±3.2	0.03	24.0±3.24	24.2±3.16	0.62
SBP, mm Hg	133.2±20.7	137.6±19.6	<0.01	139.6±23.9	137.6±19.6	0.31
DBP, mm Hg	81.8±27.7	80.3±12.0	0.39	84.4±48.9	80.3±12.0	0.21
Body temperature, ℃	37.0±0.6	37.0±0.7	0.25	37.0±0.6	37.0±0.7	0.65
Co-morbidity
Any co-morbidity	321 (37.9)	175 (74.5)	<0.01	168 (71.5)	175 (74.5)	0.47
Hypertension	227 (26.8)	147 (62.6)	<0.01	148 (63.0)	147 (62.6)	0.50
Heart disease	47 (5.5)	27 (11.5)	<0.01	22 (9.4)	27 (11.5)	0.27
Cerebrovascular disease	42 (5.0)	24 (10.3)	<0.01	27 (11.5)	24 (10.3)	0.38
Chronic kidney disease	14 (1.7)	18 (7.7)	<0.01	12 (5.1)	18 (7.7)	0.17
Chronic lung disease	56 (6.6)	16 (6.8)	0.51	18 (7.7)	16 (6.8)	0.43
Cancer	43 (5.1)	17 (7.2)	0.13	16 (6.8)	17 (7.2)	0.50
Symptoms and pneumonia
Fever	356 (42.2)	110 (46.8)	0.12	102 (43.8)	110 (46.8)	0.29
Dyspnea	194 (23.0)	74 (31.5)	<0.01	58 (24.9)	74 (31.5)	0.07
Cough	430 (50.9)	100 (42.6)	0.01	107 (45.9)	100 (42.6)	0.26
Sputum	332 (39.3)	74 (31.5)	0.02	83 (35.6)	74 (31.5)	0.20
Rhinorrhea	136 (16.1)	20 (8.5)	<0.01	33 (14.2)	20 (8.5)	0.04
Sore throat	172 (20.4)	31 (13.2)	<0.01	43 (18.5)	31 (13.2)	0.08
Myalgia	266 (31.5)	60 (25.5)	0.04	65 (27.9)	60 (25.5)	0.32
Headache	245 (29.0)	41 (17.4)	<0.01	49 (21.0)	41 (17.4)	0.19
Diarrhea	168 (19.9)	29 (12.3)	<0.01	39 (16.7)	29 (12.3)	0.11
Pneumonia	582 (68.7)	206 (87.7)	<0.01	194 (82.6)	206 (87.7)	0.08
Medication
Insulin	0	19 (8.1)		0	19 (8.1)	<0.01
Sulfonylurea	0	60 (25.5)		0	60 (25.5)	<0.01
Metformin	0	113 (48.1)		0	113 (48.1)	<0.01
α-Glucosidase inhibitor	0	2 (0.1)	0.03	0	2 (0.1)	0.03
Thiazolidinedione	0	7 (3.0)	<0.01	0	7 (3.0)	<0.01
DPP-4 inhibitor	0	85 (36.2)	<0.01	0	85 (36.2)	<0.01
SGLT-2 inhibitor	0	8 (3.4)	<0.01	0	8 (3.4)	<0.01
RAS inhibitor	105 (12.4)	70 (29.8)	<0.01	49 (20.9)	70 (29.8)	0.02
Calcium channel blocker	116 (13.7)	61 (26.0)	<0.01	70 (29.8)	61 (26.0)	0.05
β-Blocker	38 (4.5)	30 (12.8)	<0.01	23 (9.8)	30 (12.8)	0.32
Diuretic	35 (4.1)	40 (17.0)	<0.01	19 (8.1)	40 (17.0)	<0.01
Laboratory findings on admission
HbA1c, %	5.79±0.70	7.70±1.79	<0.01	5.72±0.44	7.70±1.79	<0.01
Glucose, mg/dL	109.9±30.6	186.7±101.1	<0.01	118.6±34.4	186.7±101.1	<0.01
WBCs, 103/μL	5.50±2.45	6.86±3.62	<0.01	5.99±3.06	6.86±3.62	<0.01
Neutrophils, %	60.4±14.6	69.0±15.1	<0.01	64.5±15.0	69.0±15.1	<0.01
Lymphocytes, %	28.8±12.5	21.5±12.1	<0.01	24.9±12.3	21.5±12.1	<0.01
Hb, g/dL	12.7±1.8	12.2±1.7	<0.01	12.7±4.0	12.2±1.7	0.11
Hct, %	38.1±4.6	36.4±4.9	<0.01	37.0±5.1	36.4±4.9	0.15
PLTs, 103/μL	226.2±83.3	234.0±104.3	0.23	223.9±84.3	234.0±104.3	0.25
CRP, mg/dL	7.2±21.2	10.6±18.8	0.03	9.0±22.6	10.6±18.8	0.38
Albumin, g/dL	3.93±0.49	3.64±0.56	<0.01	3.75±0.52	3.64±0.56	0.02
BUN, mg/dL	15.1±9.8	21.0±17.6	<0.01	19.1±12.6	21.0±17.6	0.18
Cr, mg/dL	0.91±1.16	1.27±1.70	<0.01	1.12±1.45	1.27±1.70	0.28
eGFR, mL/min/1.73 m2	98.8±36.0	79.7±35.1	<0.01	85.7±34.9	79.7±35.1	0.06
AST, IU/L	44.4±216.8	40.8±42.6	0.80	51.9±311.9	40.8±42.6	0.59
ALT, IU/L	33.2±107.0	30.4±33.0	0.69	33.7±145.6	30.4±33.0	0.74
LDH, IU/L	458.8±260.8	552.6±432.1	<0.01	471.2±197.2	552.6±432.1	0.01
Procalcitonin, ng/mL	0.29±2.19	0.58±3.01	0.19	0.56±3.70	0.58±3.01	0.95

Values are presented as mean±standard deviation or number (%). P values were calculated using Student's t-test or the chi-square test.

PS, propensity score; DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; DPP-4, dipeptidyl peptidase-4; SGLT-2, sodium glucose cotransporter-2; RAS, renin-angiotensin system; HbA1c, glycosylated hemoglobin; WBC, white blood cell; Hb, hemoglobin; Hct, hematocrit; PLT, platelet; CRP, C-reactive protein; BUN, blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransaminase; LDH, lactate dehydrogenase.

Table 2

In-hospital management and outcomes of patients with coronavirus disease 2019

Variable	Unmatched patients			1:1 PS-matched patients
	Non-DM	DM	P value	Non-DM	DM	P value
Treatment
ICU	73 (8.6)	57 (24.3)	<0.01	34 (14.5)	57 (24.3)	<0.01
High flow O2	52 (6.1)	35 (14.9)	<0.01	23 (9.8)	35 (14.9)	0.06
Ventilator	38 (4.5)	37 (15.7)	<0.01	18 (7.7)	37 (15.7)	<0.01
CRRT	8 (0.9)	15 (6.4)	<0.01	3 (1.3)	15 (6.4)	<0.01
ECMO	5 (0.6)	10 (4.3)	<0.01	3 (1.3)	10 (4.3)	0.04
Duration
Confirmation-releasea, day	29.4±13.6	33.2±14.3	<0.01	31.9±13.4	33.2±14.3	0.39
Hospital lengtha, day	24.6±13.3	29.3±15.1	<0.01	27.5±13.9	29.3±15.1	0.22
Outcome
Release	759 (89.6)	182 (77.4)	<0.01	207 (88.1)	182 (77.4)	<0.01
Severe disease	94 (11.1)	65 (27.7)	<0.01	45 (19.1)	65 (27.7)	0.02
Death	41 (4.8)	44 (18.7)	<0.01	18 (7.7)	44 (18.7)	<0.01

Values are presented as number (%) or mean±standard deviation. All P values were calculated using Student's t-test or the chi-square test.

PS, propensity score; DM, diabetes mellitus; ICU, intensive care unit; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation.

^aOnly includes patients who had been released from quarantine.

Table 3

Multivariate model for the prediction of severe disease or death in coronavirus disease 2019 patients

Variable	Non-DM patients		DM patients
	Severe disease	Death	Severe disease	Death
Glucose, mg/dL	1.01 (1.00–1.02)	1.02 (1.00–1.04)	1.00 (1.00–1.01)	1.00 (0.99–1.00)
WBCs, 103/μL	1.01 (0.86–1.18)	1.02 (0.78–1.34)	1.12 (1.00–1.28)	1.22 (1.06–1.41)a
Hb, g/dL	1.13 (0.93–1.36)	0.97 (0.55–1.74)	1.14 (0.82–1.59)	1.55 (1.07–2.26)b
PLT, 103/μL	1.00 (0.99–1.01)	0.99 (0.97–1.00)	0.99 (0.99–1.00)b	0.99 (0.99–1.00)b
CRP, mg/dL	1.03 (1.01–1.05)a	1.03 (0.99–1.07)	0.99 (0.96–1.01)	0.99 (0.96–1.02)
Albumin, g/dL	0.15 (0.04–0.55)a	0.53 (0.04–7.76)	0.38 (0.14–1.02)	0.19 (0.06–0.56)a
eGFR, mL/min/1.73 m2	1.00 (0.99–1.02)	1.00 (0.98–1.03)	0.99 (0.97–1.00)	0.99 (0.98–1.01)
AST, IU/L	1.09 (1.04–1.14)a	1.10 (1.02–1.19)b	1.05 (1.02–1.08)a	1.03 (1.00–1.06)b
ALT, IU/L	0.93 (0.88–0.98)a	0.93 (0.85–1.01)	0.96 (0.92–0.99)a	0.96 (0.92–1.01)
LDH, IU/L	1.00 (1.00–1.01)	1.00 (0.99–1.00)	1.00 (1.00–1.01)b	1.00 (1.00–1.00)

Data were analyzed using multivariate logistic regression, and all data are expressed as odds ratios (95% confidence intervals). The model was adjusted for age, sex, and the presence of underlying diseases.

DM, diabetes mellitus; WBC, white blood cell; Hb, hemoglobin; PLT, platelet; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransaminase; LDH, lactate dehydrogenase.

^aP<0.01, ^bP<0.05.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
  Carmen Tisch, Eleni Xourgia, Aristomenis Exadaktylos, Mairi Ziaka
  Endocrine.2024; 85(2): 660.     CrossRef
• Insulin and Metformin Administration: Unravelling the Multifaceted Association with Mortality across Various Clinical Settings Considering Type 2 Diabetes Mellitus and COVID-19
  Łukasz Lewandowski, Agnieszka Bronowicka-Szydełko, Maciej Rabczyński, Dorota Bednarska-Chabowska, Joanna Adamiec-Mroczek, Adrian Doroszko, Małgorzata Trocha, Krzysztof Kujawa, Agnieszka Matera-Witkiewicz, Edwin Kuźnik, Paweł Lubieniecki, Marcin Madziarski
  Biomedicines.2024; 12(3): 605.     CrossRef
• Prognostic Value of Hyperglycemia and Insulin Resistance Among Patients with Confirmed COVID-19 Infections at Admission to the Alexandria Fever Hospital, Egypt
  Fathy Z. Alsewy, Magdy H. Megallaa, Salma A. Imbaby, Huda M. Zidan, Heba S. Kassab, Mai H. Badrah
  Metabolic Syndrome and Related Disorders.2024; 22(7): 551.     CrossRef
• The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
  Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, Jian-Bo Zhou, Chao Zhang
  Therapeutic Innovation & Regulatory Science.2024; 58(4): 773.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• The therapeutic potential of the use of gliclazide MV in combination with COVID-19 and type 2 diabetes mellitus
  D. V. Belikina, T. A. Nekrasova, L. G. Strongin, E. M. Durygina, M. Yu. Rodina
  FOCUS. Endocrinology.2024; 5(1): 20.     CrossRef
• Research status and hotspots in the field of endoplasmic reticulum stress and liver disease: A bibliometric study
  Ruiyu Wang, Shu Huang, Ping Wang, Xiaowei Tang, Huan Xu, Wei Zhang, Lei Shi, Xiaolin Zhong, Muhan Lü, Xian Zhou, Xiaomin Shi
  Medicine.2024; 103(22): e38450.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
  Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
  Diabetes Research and Clinical Practice.2023; 195: 110205.     CrossRef
• Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
  Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
  Diabetologia.2023; 66(8): 1395.     CrossRef
• Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
  A. V. Alieva, A. A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Z. Khalilova, V. A. Talenova, N. U. Alimova, M. D. Aripova, A. S. Sadikova
  Obesity and metabolism.2023; 20(2): 92.     CrossRef
• Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
  Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
  Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
• Epidemiological features and consequences of COVID‐19 in patients with and without gastrointestinal symptoms in southwestern Iran. A retrospective observational study
  Habibollah Azarbakhsh, Leila Moftakhar, Aliasghar Valipour, Alireza Mirahmadizadeh, Hekmat Allah Moradi, Elahe Piraee
  Health Science Reports.2023;[Epub]     CrossRef
• The Impact of Long-Term Conditions and Comorbidity Patterns on COVID-19 Infection and Hospitalisation: A Cohort Study
  Yun-Ting Huang, Andrew Steptoe, Riyaz S. Patel, Esme Fuller Thomson, Dorina Cadar
  Gerontology.2023; 69(10): 1200.     CrossRef
• Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
  Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
  Archives of Medical Research.2022; 53(2): 186.     CrossRef
• Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
  Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
  Diabetes & Metabolism.2022; 48(1): 101307.     CrossRef
• Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
  Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
  Primary Care Diabetes.2022; 16(1): 162.     CrossRef
• Prevalence and impact of diabetes in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
  Sian A. Bradley, Maciej Banach, Negman Alvarado, Ivica Smokovski, Sonu M. M. Bhaskar
  Journal of Diabetes.2022; 14(2): 144.     CrossRef
• Interplay between Inflammaging, Frailty and Nutrition in Covid-19: Preventive and Adjuvant Treatment Perspectives
  A. Padilha de Lima, M. Macedo Rogero, T. Araujo Viel, H.M. Garay-Malpartida, I. Aprahamian, Sandra Maria Lima Ribeiro
  The Journal of nutrition, health and aging.2022; 26(1): 67.     CrossRef
• Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study
  Mi Seon Lee, Rosie Lee, Cheol Woo Ko, Jung Eun Moon
  Journal of Yeungnam Medical Science.2022; 39(1): 46.     CrossRef
• Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network
  Qian Gao, Wenjun Zhang, Tingting Li, Guojun Yang, Wei Zhu, Naijun Chen, Huawei Jin
  Scientific Reports.2022;[Epub]     CrossRef
• Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation
  Afnan Alshnbari, Iskandar Idris
  Current Medical Research and Opinion.2022; 38(3): 357.     CrossRef
• Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  Li-Min Zhao, Xie-Hui Chen, Mei Qiu
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• COVID-19 and Diabetes
  Awadhesh Kumar Singh, Kamlesh Khunti
  Annual Review of Medicine.2022; 73(1): 129.     CrossRef
• The enzymes in COVID-19: A review
  Maria Helena Menezes Estevam Alves, Layla Carvalho Mahnke, Tifany Cerqueira Macedo, Thais Ketinly dos Santos Silva, Luiz Bezerra Carvalho Junior
  Biochimie.2022; 197: 38.     CrossRef
• IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW
  Adnan A. Zainal, Marwan M. Merkhan
  Military Medical Science Letters.2022; 91(2): 140.     CrossRef
• Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis
  Adithan Ganesh, Michael D. Randall
  British Journal of Clinical Pharmacology.2022; 88(6): 2642.     CrossRef
• Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin
  Clifford J. Bailey, Mike Gwilt
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
  Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
  Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
• Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
  Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
  Metabolism.2022; 131: 155196.     CrossRef
• Glucose-Lowering Agents and COVID-19
  Ah Reum Khang
  The Journal of Korean Diabetes.2022; 23(1): 1.     CrossRef
• Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis
  Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
  Endocrinology, Diabetes & Metabolism.2022;[Epub]     CrossRef
• The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
  Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
  Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
  Journal of the American Heart Association.2022;[Epub]     CrossRef
• Diabetes and SARS-CoV-2–Is There a Mutual Connection?
  Anna P. Jedrzejak, Edyta K. Urbaniak, Jadwiga A. Wasko, Natalia Ziojla, Malgorzata Borowiak
  Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
• The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2022; 11: 729.     CrossRef
• Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?
  Marzieh Rohani-Rasaf, Kosar Mirjalili, Akram Vatannejad, Maryam Teimouri, Xiao-Feng Yang
  PLOS ONE.2022; 17(8): e0272000.     CrossRef
• Early glycaemic variability increases 28-day mortality and prolongs intensive care unit stay in critically ill patients with pneumonia
  Seong Ho Kim, Ji Young Kim, Eun Song Kim, Il Rae Park, Eun Yeong Ha, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
  Annals of Medicine.2022; 54(1): 2724.     CrossRef
• Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
  Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
  World Journal of Virology.2022; 11(6): 399.     CrossRef
• Prevalencia de secuelas en pacientes con diabetes mellitus tipo 2 sobrevivientes al COVID-19
  Gianela M. Cancino-Castillo, Miguel A. Tresierra-Ayala, Jorge L. Campos-Reyna, Jaime Rosales-Rimache
  REVISTA MÉDICA VALLEJIANA/ Vallejian Medical Journal.2022; 11(2): 48.     CrossRef
• Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq
  Hussein Nafakhi, Mohammed Alareedh, Karrar Al-Buthabhak, Foaad Shaghee, Ahmed Nafakhi, Samet Kasim
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 33.     CrossRef
• Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
  Awadhesh Kumar Singh, Ritu Singh, Banshi Saboo, Anoop Misra
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 159.     CrossRef
• COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis
  Mark Thomaz Ugliara Barone, Belinda Ngongo, Simone Bega Harnik, Lucas Xavier de Oliveira, Dániel Végh, Patrícia Vieira de Luca, Hermelinda Cordeiro Pedrosa, Franco Giraudo, Roque Cardona-Hernandez, Nayanjeet Chaudhury, Luiz Menna-Barreto
  Diabetes Research and Clinical Practice.2021; 171: 108587.     CrossRef
• A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
  Chia Siang Kow, Syed Shahzad Hasan
  Therapies.2021; 76(4): 361.     CrossRef
• Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
  B. M. Bonora, A. Avogaro, G. P. Fadini
  Journal of Endocrinological Investigation.2021; 44(7): 1379.     CrossRef
• Prognostic bioindicators in severe COVID-19 patients
  L. Bergantini, E. Bargagli, M. d'Alessandro, R.M. Refini, P. Cameli, L. Galasso, C. Scapellato, F. Montagnani, S. Scolletta, F. Franchi, S. Valente, D. Bennett, G. Sebastiani, B. Frediani, F. Dotta
  Cytokine.2021; 141: 155455.     CrossRef
• Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients
  Leila Moftakhar, Parisa Moftakhar, Elahe Piraee, Haleh Ghaem, Aliasghar Valipour, Habibollah Azarbakhsh
  International Journal of Diabetes in Developing Countries.2021; 41(3): 383.     CrossRef
• DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
  André J. Scheen
  Diabetes & Metabolism.2021; 47(2): 101213.     CrossRef
• Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
  Ronan Roussel, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, Leila Ait Bachir, Ingrid Allix, Deborah Ancelle, Sara Barraud, Lyse Bordier, Aurélie Carlier, Nicolas Chevalier, Christine Coffin‐Boutreux, Emmanuel Cosson, Anne Dorange, O
  Diabetes, Obesity and Metabolism.2021; 23(5): 1162.     CrossRef
• Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis
  Rimesh Pal, Mainak Banerjee, Soham Mukherjee, Ranjitpal Singh Bhogal, Amanpreet Kaur, Sanjay K. Bhadada
  Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub]     CrossRef
• Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
  Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, Giovanni Corrao, Franz H. Messerli
  Journal of Hypertension.2021; 39(4): 784.     CrossRef
• Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis
  Zeinab Abdelrahman, Qian Liu, Shanmei Jiang, Mengyuan Li, Qingrong Sun, Yue Zhang, Xiaosheng Wang
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
  Timotius Ivan Hariyanto, Andree Kurniawan
  Journal of Diabetes & Metabolic Disorders.2021; 20(1): 543.     CrossRef
• Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis
  Halla Kaminska, Lukasz Szarpak, Dariusz Kosior, Wojciech Wieczorek, Agnieszka Szarpak, Mahdi Al-Jeabory, Wladyslaw Gawel, Aleksandra Gasecka, Milosz J. Jaguszewski, Przemyslawa Jarosz-Chobot
  Acta Diabetologica.2021; 58(8): 1101.     CrossRef
• Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression
  Iis Inayati Rakhmat, Yudith Yunia Kusmala, Dewi Ratih Handayani, Henny Juliastuti, Eka Noneng Nawangsih, Arief Wibowo, Michael Anthonius Lim, Raymond Pranata
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(3): 777.     CrossRef
• Post-infection depressive, anxiety and post-traumatic stress symptoms: A prospective cohort study in patients with mild COVID-19
  Flavia Ismael, João C.S. Bizario, Tatiane Battagin, Beatriz Zaramella, Fabio E. Leal, Julio Torales, Antonio Ventriglio, Megan E. Marziali, Silvia S. Martins, João M. Castaldelli-Maia
  Progress in Neuro-Psychopharmacology and Biological Psychiatry.2021; 111: 110341.     CrossRef
• Managing diabetes in diabetic patients with COVID: where do we start from?
  Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
  Acta Diabetologica.2021; 58(11): 1441.     CrossRef
• Is diabetes mellitus a wrongdoer to COVID-19 severity?
  Sanjib Sarkar, Dibyendu Das, Sawlang Borsingh Wann, Jatin Kalita, Prasenjit Manna
  Diabetes Research and Clinical Practice.2021; 178: 108936.     CrossRef
• Dipeptidyl Peptidase 4 Inhibitor, an Update
  Ju Hee Lee
  The Journal of Korean Diabetes.2021; 22(2): 91.     CrossRef
• Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19
  Zhenmu Jin, Mo Zheng, Jichan Shi, Xinchun Ye, Fang Cheng, Que-Lu Chen, Jianping Huang, Xian-Gao Jiang
  Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
• Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
  Anna R. Kahkoska, Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Stürmer, Kajsa Kvist, John B. Buse, Tim Q. Duong
  Diabetes Care.2021; 44(7): 1564.     CrossRef
• The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus
  Wenxing Yang, Xuehong Sun, Jun Zhang, Kui Zhang
  Diabetes Research and Clinical Practice.2021; 178: 108977.     CrossRef
• Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
  Jordan Loader, Erik Lampa, Stefan Gustafsson, Thomas Cars, Johan Sundström
  Journal of the American Heart Association.2021;[Epub]     CrossRef
• Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus
  Ayça Elibol, Didem Eren, Macide Deniz Erdoğan, Merve Elmaağaç, Oguzhan Sıtkı Dizdar, İlhami Çelik, Ali İhsan Günal
  Primary Care Diabetes.2021; 15(5): 806.     CrossRef
• Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors
  Melina Farshbafnadi, Sara Kamali Zonouzi, Mohammadmahdi Sabahi, Mahsa Dolatshahi, Mohammad Hadi Aarabi
  Experimental Gerontology.2021; 154: 111507.     CrossRef
• Classical and Counter-Regulatory Renin–Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology
  Moudhi Almutlaq, Abir Abdullah Alamro, Fayhan Alroqi, Tlili Barhoumi
  CJC Open.2021; 3(8): 1060.     CrossRef
• Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
  Yin Li, Xue Yang, Peijing Yan, Tong Sun, Zhi Zeng, Sheyu Li
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
  Marina Treskova-Schwarzbach, Laura Haas, Sarah Reda, Antonia Pilic, Anna Borodova, Kasra Karimi, Judith Koch, Teresa Nygren, Stefan Scholz, Viktoria Schönfeld, Sabine Vygen-Bonnet, Ole Wichmann, Thomas Harder
  BMC Medicine.2021;[Epub]     CrossRef
• COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
  Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
  Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
• High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
  Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
  Endocrinology and Metabolism.2021; 36(4): 800.     CrossRef
• Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  Chengxia Kan, Yang Zhang, Fang Han, Qian Xu, Tongtong Ye, Ningning Hou, Xiaodong Sun
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
  E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
  Kardiologiia.2021; 61(9): 20.     CrossRef
• Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
  Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
  Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545.     CrossRef
• COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
  Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis
  Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
  SSRN Electronic Journal .2021;[Epub]     CrossRef
• Decision Trees: Predictions of Global Vulnerability to Coronavirus Outbreaks
  Moacir José da Silva
  SSRN Electronic Journal .2020;[Epub]     CrossRef
• The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis
  Liman Luo, Menglu Fu, Yuanyuan Li, Shuiqing Hu, Jinlan Luo, Zhihui Chen, Jing Yu, Wenhua Li, Ruolan Dong, Yan Yang, Ling Tu, Xizhen Xu
  Clinical Cardiology.2020; 43(12): 1478.     CrossRef
• The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
  Antonia Anna Lukito, Raymond Pranata, Joshua Henrina, Michael Anthonius Lim, Sherly Lawrensia, Ketut Suastika
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2177.     CrossRef
• Risk Factors on the Progression to Clinical Outcomes of COVID-19 Patients in South Korea: Using National Data
  Seon-Rye Kim, Seoul-Hee Nam, Yu-Rin Kim
  International Journal of Environmental Research and Public Health.2020; 17(23): 8847.     CrossRef
• Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea
  Ji Hong You, Sang Ah Lee, Sung-Youn Chun, Sun Ok Song, Byung-Wan Lee, Dae Jung Kim, Edward J. Boyko
  Endocrinology and Metabolism.2020; 35(4): 901.     CrossRef

About this article

Kim MK, Jeon JH, Kim SW, Moon JS, Cho NH, Han E, You JH, Lee JY, Hyun M, Park JS, Kwon YS, Choi YK, Kwon KT, Lee SY, Jeon EJ, Kim JW, Hong HL, Kwon HH, Jung CY, Lee YY, Ha E, Chung SM, Hur J, Ahn JH, Kim Ny, Kim SW, Chang HH, Lee YH, Lee J, Park KG, Kim HA, Lee JH. The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea. Diabetes Metab J. 2020;44(4):602-613.

Received: Jun 26, 2020; Accepted: Jul 02, 2020

DOI: https://doi.org/10.4093/dmj.2020.0146.

Download citation ↓